Stelara (Ustekinumab) 90mg/1mL SC Prefilled Syringe

$29,995.00

*** To Save ($26,500) Click Here: Yesintek: Biosimilar to Stelara 90 mg PreFilled Syringe ($3495)***

*** To Save ($25,500) Click Here: Selarsdi: Biosimilar to Stelara 90 mg PreFilled Syringe ($4495)***

*** To Save ($25,000) Click Here: Steqeyma: Biosimilar to Stelara 90 mg PreFilled Syringe ($5995)***

*** To Save ($24,000) Click Here: Wezlana: Biosimilar to Stelara 90 mg PreFilled Syringe ($5995)***

– Prescription Required
– Free Next Day Delivery to Anywhere in CA and NY
– Free Same Day Delivery within 50-Mile Radius of ApoThera
– Concierge Pharmacy; Do NOT Accept Insurance
– Annual Concierge Pharmacy Membership Fee: $300/year
– Accept Credit Cards, Apple Pay and Zelle
– Do NOT accept manufacturer coupons
 
Physicians may send E-Prescriptions (E-Scripts) to:
ApoThera
45 Post, 2nd Floor
Irvine, CA 92618
Phone: (949)387-7711
Fax:      (949)387-7712
Crohn Disease
Induction 
– ≤55 kg: 260 mg IV x 1 dose
– 55 kg to 85 kg: – 390 mg IV x 1 dose
– >85 kg: 520 mg IV x 1 dose
Maintenance Dose
– 90 mg SC every 8 weeks
– Begin maintenance dosing 8 weeks after the IV induction dose
Plaque Psoriasis
Dosing ≤100 kg
– 45 mg SC at 0 and 4 weeks
THEN,
– 45 mg SC every 12 weeks thereafter
Dosing >100 kg
– 90 mg SC at 0 and 4 weeks
THEN,
– 90 mg SC every 12 weeks thereafter
– Doses of 45 mg SC given to patients >100 kg were also efficacious; however, 90 mg is the recommended dose in these patients due to greater efficacy.
Psoriatic Arthritis
– Treatment of active psoriatic arthritis (as monotherapy or in combination with methotrexate) in adults
– When used for psoriatic arthritis, may be administered alone or in combination with methotrexate.
Initial Dose
– 45 mg at 0 and 4 weeks
Maintenance Dose
– 45 mg every 12 weeks thereafter.
Manufacturer: Janssen Biotech
NDC: 57894-0061-03 Category:

1 Syringe = 1 Unit

Description

Drug Info: ApoThera Drug Disease Clinical Support App

SC Administration
– Administer by subcutaneous injection into the top of the thigh, abdomen, upper arms, or buttocks
– Rotate sites
– Do not inject into tender, bruised, erythematous, or indurated skin
– Avoid areas of skin where psoriasis is present
– Discard any unused portion
– Intended for use under supervision of physician; self-injection may occur after proper training
 
Storage
– Refrigerate prefilled syringes at 2°C to 8°C (36°F to 46°F)
– Do not freeze
– Store vials upright
– Keep the product in the original carton to protect from light until the time of use.
– Do not shake.
– Discard any unused portion
 
Monitoring
– Tuberculosis screening (prior to initiating and periodically during therapy)
– CBC
– Ustekinumab-antibody formation
– Signs and symptoms of infection, reversible posterior leukoencephalopathy syndrome (RPLS), and squamous cell skin carcinoma
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Related Products